![\"Video](\"https:\/\/www.dumonceau-urologie.fr\/wp-content\/uploads\/2026\/04\/comment-savoir-si-mon-cancer-de-prostate-est-agressif-vtb-69e23817b2cde.jpg\")
<\/p>\n<\/p>\n
When you learn you have prostate cancer, the first question that almost always comes up is simple and essential: is it an aggressive cancer or not?<\/strong><\/p>\n Fortunately, today prostate cancer is a very well-defined disease. We have reliable tools to assess the situation, classify the severity of the tumor, and propose appropriate treatment. In other words, we don't just say there's cancer. We try to understand what type of cancer it is, how far it has spread, and how likely it is to progress<\/strong> .<\/p>\n This assessment is based on several examinations carried out at the time of diagnosis, and then on well-established medical classifications.<\/p>\n Before discussing classification, it's important to remember what it's based on. The aggressiveness of prostate cancer cannot be judged intuitively. It is determined based on a combination of clinical and biological factors.<\/p>\n In practice, the evaluation is generally based on:<\/p>\n It is at the end of this process that it becomes possible to specify:<\/p>\n This step is crucial because not all prostate cancers are the same. Some progress very slowly and can simply be monitored. Others require immediate treatment, sometimes even a combination of therapies.<\/p>\n The first major way to classify cancer is the TNM classification<\/a><\/strong> . It is used in oncology in general, not just for prostate cancer.<\/p>\n TNM means:<\/p>\n This is a progressive classification, which describes the extent of the disease.<\/p>\n Stage T<\/strong> describes the tumor in the prostate and its surroundings.<\/p>\n The higher the T stage, the more advanced the tumor is locally.<\/p>\n Stage N<\/strong> specifies whether lymph nodes are affected.<\/p>\n Stage M<\/strong> indicates whether the disease has spread over a distance.<\/p>\n The TNM classification is useful, even indispensable, but for prostate cancer, it sometimes remains a little too general to guide therapeutic decisions on its own.<\/p>\n Two patients can have localized prostate cancer and yet not have the same risk of progression. What makes the difference is not only the anatomical extent of the tumor, but also its biological behavior.<\/p>\n For this reason, in practice, a classification more specific to prostate cancer is very widely used: the D'Amico classification<\/a><\/strong> .<\/p>\n The D'Amico classification is now a central reference point in the management of prostate cancer. It allows patients to be divided into three groups based on their 10-year risk of recurrence<\/strong> :<\/p>\n This classification is based primarily on three elements:<\/p>\n The Gleason score, established from prostate biopsies, indicates the aggressiveness of cancer cells. The higher it is, the more potentially aggressive the cancer.<\/p>\n We speak of low risk<\/strong> when dealing with a small, localized tumor, with reassuring criteria:<\/p>\n These are the least aggressive forms. And this is a very important point: prostate cancer does not automatically imply immediate treatment<\/strong> .<\/p>\n Today, for many low-risk tumors, the most frequently proposed strategy is active surveillance<\/a><\/strong> .<\/p>\n This means that surgery and radiotherapy are not used as the initial treatment. The cancer is rigorously monitored with scheduled checkups, intervening only if the situation changes. This approach has profoundly changed modern treatment, avoiding unnecessary procedures in patients with very slow-growing cancers.<\/p>\n The intermediate<\/strong> group corresponds to more aggressive tumors, but which often remain curable with well-conducted treatment.<\/p>\n The following situations are generally found there:<\/p>\n In this category, treatment is generally necessary. It is often a simple treatment<\/strong> , that is to say:<\/p>\n The choice between the two depends on many medical and personal parameters, but the essential idea is that these cancers most often justify active treatment.<\/p>\n We speak of high risk<\/strong> when several signs indicate a more aggressive disease:<\/p>\n In this context, the risk of progression or recurrence is higher. The therapeutic strategy may then be more intensive.<\/p>\n It may be necessary to offer combined treatment<\/strong> , that is to say, to combine several approaches, for example surgery and radiotherapy<\/strong> .<\/p>\n The goal is to maximize disease control, taking into account that these tumors have a greater potential for progression.<\/p>\n In practice, when trying to determine if prostate cancer is aggressive, three main things are looked at:<\/p>\n Therefore, it is never a single isolated result that determines the severity of the situation. It is the overall assessment that allows for an accurate view of the situation.<\/p>\n The value of all these classifications is not merely academic. They serve to answer a very concrete question: what treatment should be offered?<\/strong><\/p>\n Very schematically:<\/p>\n This clearly illustrates the evolution of modern prostate medicine. We're no longer in a situation where all cancers had to be treated immediately and in the same way. Treatment is now personalized<\/strong> , based on the specific profile of the cancer.<\/p>\n Learning that you have prostate cancer is obviously a difficult experience. But it's important to know that there are now very reliable tools available to assess its severity.<\/p>\n Thanks to PSA<\/a> testing, MRI<\/a> , prostate biopsies, the Gleason score, the TNM classification, and especially the D'Amico classification, it is possible to determine precisely whether one is dealing with:<\/p>\n And this distinction changes everything, because it makes it possible to avoid both under-processing and over-processing.<\/p>\n <\/p> Tests that help assess the aggressiveness of the cancer<\/h2>\n
\n
\n
First classification: the TNM classification<\/h2>\n
\n
Stage T: the tumor itself<\/h3>\n
\n
Stage N: the lymph nodes<\/h3>\n
\n
Stage M: Metastases<\/h3>\n
\n
Why the TNM classification is not always sufficient<\/h2>\n
The D'Amico classification: assessing the 10-year risk of recurrence<\/h2>\n
\n
\n
1. Low-risk prostate cancer<\/h3>\n
\n
2. Intermediate-risk prostate cancer<\/h3>\n
\n
\n
3. High-risk prostate cancer<\/h3>\n
\n
What truly determines the aggressiveness of prostate cancer<\/h2>\n
\n
Why this classification is essential for treatment<\/h2>\n
\n
One key idea to remember<\/h2>\n
\n
Video<\/h2>\n